New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:38 EDTBCR, MDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Wells fargo believes that data from a trial of Medtronic's drug-coated balloon will lead to approval of the device in 1H15 and establish the company as the market leader in the space. After analyzing data, the firm thinks data on a competing device from C.R. Bard (BCR) could be significantly less positive than the data on Medtronic's product. As a result, the firm anticipates that Medtronic will have a marketing advantage over C.R. Bard. Wells keeps an Outperform rating on Medtronic.
News For MDT;BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
08:42 EDTMDTMedtronic coverage resumed with a Buy at Goldman
Subscribe for More Information
January 26, 2015
17:06 EDTMDTMedtronic completes acquisition of Covidien for $49.9B
Subscribe for More Information
07:17 EDTMDTSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
07:08 EDTMDTMedtronic pending acquisition of Covidien approved by Irish High Court
Subscribe for More Information
January 23, 2015
16:33 EDTMDTMedtronic reports 5.1% passive stake in Intersect ENT
Subscribe for More Information
15:46 EDTMDTPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTMDTMedtronic receives FDA approval for for the Medtronic Enterra II System
Subscribe for More Information
January 21, 2015
18:06 EDTMDTS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
January 20, 2015
06:32 EDTBCRC.R. Bard upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use